Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:AMCR NYSE:CVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$249.98-1.1%$224.54$184.63▼$261.64$446.54B0.38.90 million shs5.52 million shsAMCRAmcor$42.71+1.8%$40.10$36.25▼$50.94$19.40B0.623.20 million shs2.49 million shsCVXChevron$174.05-1.1%$182.23$146.49▼$214.71$350.46B0.59.42 million shs6.57 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-1.18%-4.18%+10.98%+20.06%+31.06%AMCRAmcor+1.90%-5.06%+9.91%+3.67%-12.93%CVXChevron-1.05%+2.95%-6.82%-7.70%+13.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$249.98-1.1%$224.54$184.63▼$261.64$446.54B0.38.90 million shs5.52 million shsAMCRAmcor$42.71+1.8%$40.10$36.25▼$50.94$19.40B0.623.20 million shs2.49 million shsCVXChevron$174.05-1.1%$182.23$146.49▼$214.71$350.46B0.59.42 million shs6.57 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-1.18%-4.18%+10.98%+20.06%+31.06%AMCRAmcor+1.90%-5.06%+9.91%+3.67%-12.93%CVXChevron-1.05%+2.95%-6.82%-7.70%+13.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.84Moderate Buy$258.193.28% UpsideAMCRAmcor 2.73Moderate Buy$48.0012.39% UpsideCVXChevron 2.69Moderate Buy$205.7118.19% UpsideCurrent Analyst Ratings BreakdownLatest AMCR, CVX, and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026ABBVAbbVie GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$249.00 ➝ $261.007/9/2026ABBVAbbVie JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $280.007/6/2026ABBVAbbVie HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$300.007/6/2026ABBVAbbVie Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$240.00 ➝ $265.007/2/2026CVXChevron Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$210.006/29/2026CVXChevron Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$214.00 ➝ $210.006/23/2026ABBVAbbVie Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform6/23/2026CVXChevron UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/23/2026ABBVAbbVie Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/23/2026ABBVAbbVie Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$265.00 ➝ $273.006/23/2026ABBVAbbVie Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$298.00(Data available from 7/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B7.22$14.98 per share16.69($1.83) per share-136.60AMCRAmcor$15.01B1.32$4.18 per share10.21$25.47 per share1.68CVXChevron$189.03B1.83$16.53 per share10.53$95.44 per share1.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03123.1415.590.835.79%-576.45%13.39%7/31/2026 (Estimated)AMCRAmcor$511M$1.4329.8710.031.183.06%14.55%4.57%8/19/2026 (Estimated)CVXChevron$12.30B$5.7730.1612.830.605.79%6.90%4.06%7/31/2026 (Estimated)Latest AMCR, CVX, and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2026Q2 2026ABBVAbbVie$3.76N/AN/AN/A$16.77 billionN/A7/31/2026Q2 2026CVXChevron$5.10N/AN/AN/A$63.24 billionN/A5/5/2026Q3 2026AMCRAmcor$0.96$0.96N/A$0.60$5.71 billion$5.91 billion5/1/2026Q1 2026CVXChevron$1.00$1.41+$0.41$1.11$51.86 billion$47.56 billion4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.922.77%+6.80%340.89%53 YearsAMCRAmcor$2.606.09%+1.74%181.82%5 YearsCVXChevron$7.124.09%+5.80%123.40%38 YearsLatest AMCR, CVX, and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/18/2026ABBVAbbViequarterly$1.733.19%7/15/20267/15/20268/14/20265/6/2026AMCRAmcorquarterly$0.656.62%5/28/20265/28/20266/17/20264/29/2026CVXChevronquarterly$1.783.61%5/19/20265/19/20266/10/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68AMCRAmcor1.301.440.95CVXChevron0.211.090.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%AMCRAmcor45.14%CVXChevron72.42%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%AMCRAmcor0.32%CVXChevron0.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableAMCRAmcor77,000462.35 million460.87 millionOptionableCVXChevron43,0391.99 billion1.98 billionOptionableAMCR, CVX, and ABBV HeadlinesRecent News About These CompaniesChevron Signs Five-Year WA Gas Supply Deal With Alinta Energy12 minutes ago | finance.yahoo.comMain Street Research LLC Purchases 7,331 Shares of Chevron Corporation $CVX2 hours ago | marketbeat.comKestra Advisory Services LLC Purchases 16,625 Shares of Chevron Corporation $CVX2 hours ago | marketbeat.comSumitomo Mitsui Trust Group Inc. Decreases Holdings in Chevron Corporation $CVX2 hours ago | marketbeat.comResona Asset Management Co. Ltd. Has $129.77 Million Position in Chevron Corporation $CVX2 hours ago | marketbeat.comElevated Capital Advisors LLC Reduces Holdings in Chevron Corporation $CVX3 hours ago | marketbeat.comFirst Horizon Corp Boosts Holdings in Chevron Corporation $CVX3 hours ago | marketbeat.comChevron Australia signs five-year gas supply agreement with Alinta EnergyJuly 9 at 10:47 PM | reuters.comChevron (NYSE:CVX) Stock Price Down 1.1% - Time to Sell?July 9 at 5:19 PM | marketbeat.comChevron (NYSE:CVX): Can Oil Strength Power The Next Move?July 9 at 3:32 PM | kalkinemedia.comKCVX Stock Has A New Bull Case — Why Bank Of America Favors Chevron Over Exxon As Hormuz Risks Push Oil Prices HigherJuly 9 at 3:32 PM | stocktwits.comSAre Energy Stocks Still A Long-Term Buy (Technical Analysis)?July 9 at 1:00 PM | seekingalpha.comWhere to Invest Now as US Stock Markets Get BubblyJuly 9 at 10:32 AM | finance.yahoo.comMetalworking Fluids Market, Till 2035 Report Published; Profiles Chevron, ExxonMobil Chemical, Quaker Houghton, Fuchs, Lubrizol, and 15 Other Key PlayersJuly 9 at 10:32 AM | finance.yahoo.comChevron’s (CVX) Data Center Ambitions Are A Great Way To Play The AI Power BottleneckJuly 9 at 10:32 AM | finance.yahoo.comChevron (CVX) Faces DOJ Probe As Iran Tensions Raise Record Profit StakesJuly 9 at 10:32 AM | finance.yahoo.comChevron's New Technology Licensing Deal to Boost Shale Oil RecoveryJuly 9 at 10:32 AM | finance.yahoo.comWith Iran Tensions Heating Up Again, Chevron Stock Looks EnticingJuly 9 at 10:11 AM | barchart.comChevron's New Technology Licensing Deal to Boost Shale Oil RecoveryJuly 9 at 9:56 AM | zacks.comExxonMobil vs. Chevron: Which Oil Dividend Stock is the Better Buy for a Lifetime of Passive IncomeJuly 9 at 6:51 AM | fool.comChevron Corporation $CVX Stock Position Reduced by Munich Reinsurance Co Stock Corp in MunichJuly 9 at 6:23 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Draining the Tank: Big Oil Runs on FumesBy Jeffrey Neal Johnson | June 17, 20263 Stocks to Watch If the Strait of Hormuz ReopensBy Chris Markoch | June 17, 2026Chevron’s Microsoft Deal Turns Natural Gas Into an AI TradeBy Jeffrey Neal Johnson | June 24, 2026Microsoft Solves AI’s Biggest Bottleneck With Chevron DealBy Chris Markoch | June 25, 2026AMCR, CVX, and ABBV Company DescriptionsAbbVie NYSE:ABBV$249.98 -2.76 (-1.09%) Closing price 07/9/2026 03:59 PM EasternExtended Trading$250.70 +0.71 (+0.29%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Amcor NYSE:AMCR$42.71 +0.76 (+1.81%) Closing price 07/9/2026 03:59 PM EasternExtended Trading$42.37 -0.34 (-0.80%) As of 07:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amcor plc develops, produces, and sells packaging products in Europe, North America, Latin America, Africa, and the Asia Pacific regions. The company operates through two segments, Flexibles and Rigid Packaging. The Flexibles segment provides flexible and film packaging products in the food and beverage, medical and pharmaceutical, fresh produce, snack food, personal care, and other industries. The Rigid Packaging segment offers rigid containers for various beverage and food products, including carbonated soft drinks, water, juices, sports drinks, milk-based beverages, spirits and beer, sauces, dressings, spreads, and personal care items; and plastic caps for various applications. The company sells its products through its direct sales force. Amcor plc was incorporated in 2018 and is headquartered in Zurich, Switzerland.Chevron NYSE:CVX$174.05 -1.92 (-1.09%) Closing price 07/9/2026 03:59 PM EasternExtended Trading$174.72 +0.67 (+0.39%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Chevron Corporation, through its subsidiaries, engages in the integrated energy and chemicals operations in the United States and internationally. The company operates in two segments, Upstream and Downstream. The Upstream segment is involved in the exploration, development, production, and transportation of crude oil and natural gas; processing, liquefaction, transportation, and regasification of liquefied natural gas; transportation of crude oil through pipelines; transportation, storage, and marketing of natural gas; and carbon capture and storage, as well as a gas-to-liquids plant. The Downstream segment refines crude oil into petroleum products; markets crude oil, refined products, and lubricants; manufactures and markets renewable fuels, commodity petrochemicals, plastics for industrial uses, and fuel and lubricant additives; and transports crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car. The company was formerly known as ChevronTexaco Corporation and changed its name to Chevron Corporation in 2005. Chevron Corporation was founded in 1879 and is headquartered in San Ramon, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Dollar Tree’s Turnaround Is Starting to Take Root Constellation Brands: Beer Growth and Buybacks Mask Stock's Slump Grounded: SpaceX Stumbles as Grok Fails to Ignite Southwest MAX Incident Revives Headline Risk for Boeing and Airline Stocks Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and Mastercard Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
